Bronchial artery embolization for hemoptysis: A systematic review and meta-analysis

Zhiyuan Zheng\textsuperscript{a,b,1}, Zhiquan Zhuang\textsuperscript{a,b,1}, Minjie Yang\textsuperscript{a}, Jianjun Luo\textsuperscript{a}, Wen Zhang\textsuperscript{a,b,**}, Zhiping Yan\textsuperscript{a,b,*}, Xiaolin Wang\textsuperscript{a,b,***}

\textsuperscript{a} Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China
\textsuperscript{b} Shanghai Institute of Medical Imaging, Shanghai, China

\textbf{A B S T R A C T}

Objective: To assess the safety and efficacy of bronchial artery embolization (BAE) for hemoptysis.

Methods and materials: Databases with articles published in English, including Pubmed, Embase, Web of science and Chochrane library, were comprehensively searched to get accurate, up-to-date and sufficient literature about BAE for hemoptysis until March 2020. The technical success rates, immediate control rates, recurrence rates, mortality rates, and total complication rates (minor and major complication rates) extracted from the articles were pooled to estimate and assess the efficacy and safety of BAE using random-effect and fixed-effect models.

Results: 21 articles published between 2008 and 2019, which include a total of 2511 patients, were studied to evaluate the safety and efficacy of BAE. The technical success and immediate control rates are 99.9% (95%CI: 99%-100%) and 99.5% (95%CI: 97.8%-99.2%), respectively. This study showed hemoptysis recurrence in 23.7% (95%CI: 18.5%-28.9%) with a mortality rate of 2% (95%CI: 0.3%). Additionally, the assessment of complications revealed a total complication rate of 13.4% (95% CI: 7.6–19.2%), in which 0.2% (95% CI: 0.2–0.4%) were major complications and 10% (95% CI: 4.7–9.6%) were minor complications.

Conclusion: BAE is an effective, safe, and feasible procedure with a low complication rate for hemoptysis patients. However, recurrence of hemoptysis is still at high risk after BAE due to different underlying diseases.

1. Introduction

Hemoptysis\textsuperscript{1} is defined as the expectoration of blood, alone or in combination with mucus, from the lower respiratory tract. In a cohort study involving 762325 patients, hemoptysis occurred in 4812 patients as an alarm symptom.\textsuperscript{2} Etiological surveys have shown that the most common causes of hemoptysis are airway infections, bronchial carcinoma/-metastases, and bronchiectasis/cystic fibrosis.\textsuperscript{3} Generally, hemoptysis can be classified as bloody sputum, mild (<10 mL/d), moderate (100–500 mL/d), or massive hemoptysis (>500 mL/d). Massive hemoptysis can be life-threatening because massive bleeding obstructs the airways. Researchers have reported that the mortality rate of severe hemoptysis was over 50% in uncontrolled bleeding\textsuperscript{4}; therefore, the diagnosis and treatment of hemoptysis should be implemented immediately.

Mild or moderate hemoptysis is often treated with vasoactive drugs and conservative treatment measures, whereas massive hemoptysis requires more aggressive management, including bronchoscopy and surgical treatment.\textsuperscript{5} Bronchoscopy has clinical significance in controlling bleeding and protecting airways, and its immediate massive hemoptysis control rate is nearly 100%.\textsuperscript{5} However, the hemostatic effect of bronchoscopy usually last for a short time. Therefore, other procedures should be immediately taken to achieve durable hemostasis when bronchoscopy exerts a poor effect on acute bleeding. From another perspective, the therapeutic effects of bronchoscopy might be constrained when the bleeding site is beyond the reach of bronchoscopy. Surgical treatment is often the second-line therapy for hemoptysis, but the mortality rate of patients who received surgery was approximately 40%.\textsuperscript{6,7} Additionally, patients with poor lung function, bilateral pulmonary lesions, and other complications may not be suitable for surgery. The hospitalization rate of surgical patients is significantly higher than that of nonsurgical patients.\textsuperscript{8} Therefore, the use of bronchial artery embolization (BAE) is increasingly considered as a safe and effective first-line treatment option for hemoptysis.

\textsuperscript{1} Corresponding author. Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.

\textsuperscript{**} Corresponding author. Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.

\textsuperscript{***} Corresponding author. Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.

E-mail addresses: 20111320006@fudan.edu.cn (Z. Zheng), 19211320003@fudan.edu.cn (Z. Zhuang), zhang.wen2@zs-hospital.sh.cn (W. Zhang), yan.zhiping@zs-hospital.sh.cn (Z. Yan), wang.xiaolin@zs-hospital.sh.cn (X. Wang).

\textsuperscript{1} Contributed equally to the manuscript.
comorbidities are not candidates for surgery.

Considering that the bronchial arteries are the culprit vessels of hemoptysis, bronchial artery embolization (BAE) was first introduced as a minimally invasive endovascular treatment for hemoptysis in 1973. Since then, BAE has been widely used for hemoptysis. The technique has improved significantly, especially with the emergence of the “super-selective” BAE, which improved the immediate bleeding control rate to >70%. In addition, the procedure can be safely performed even in recurrent hemoptysis. Severe BAE procedure-related complications are rare. At present, BAE is considered an effective method for treating massive or recurrent hemoptysis. An array of clinical trials has been conducted to evaluate the clinical effects of the BAE in managing hemoptysis; however, the meta-analysis on this method is still lacking. This meta-analysis aimed to analyze the efficacy and safety of BAE in the treatment of hemoptysis and provide evidence for guidelines.

2. Method and materials

2.1. Study selection

To assess the efficacy and safety of BAE in patients with hemoptysis, two researchers (Zheng and Zhuang) individually searched the online literature databases of PubMed, Embase, Web of Science, and Cochrane Library, in accordance with March 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search strategies were as follows: bronchial artery embolization (BAE) and hemoptysis. Additional literature was searched and screened manually. The discrepancy concerning article selection was resolved by another author after analysis and discussion. The Institutional Review Board approval or exemption was not necessary for this study due to no original human and animal information.

2.2. Included and excluded criteria

Rigorous literature publication inclusion standards have been established, and only studies that met all of the criteria were included. The inclusion criteria for the studies were as follows: (1) original study is in English or Chinese; (2) the patients presented with massive or moderate hemoptysis; (3) patients with hemoptysis show ineffectiveness after pharmacologic treatment and endoscopy; (4) the patients were treated by embolotherapy; (5) follow-up data was complete and with a follow-up duration of >3 three months; (6) clinical outcomes were reported with the proportions in the article (i.e., technical success, recurrence rate, mortality rate, major complications, and minor complications); and (7) publication date between 2009 and 2020.

Studies were excluded if they met any one of the criteria as follows: (1) review article, systematic review, meta-analysis, comments, discussion, editorials, case reports, animal experiments, and conference papers; (2) duplicate articles reporting the same data; (3) studies without prognostic and survival data; and (4) full-texts were not retrieved, and attempts to contact the author but failed.

2.3. Data extraction

Two investigators (Zheng and Zhuang) independently screened all articles and extracted relevant data from each research based on the established protocol. Any disagreements regarding data extraction were addressed by consensus after discussion. The demographics, characteristics, and primary clinical outcome data were extracted, including author, year, country, number of patients, sex, etiology, technical success rate, immediate control rate, total recurrence rate, major complication rate, minor complication rate, and mortality rate after BAE.

Technical success was defined as successful embolization of targeted arteries, and immediate success was defined as the absence of bleeding within 24 h post-BAE. Total recurrence was defined as post-BAE recurrence of hemoptysis during follow-up, as reported in a previous study. The recurrence mortality rate of hemoptysis was the death rate in recurrent hemoptysis patients. Major complications were defined as unplanned sequelae that may require medical intervention during hospitalization or even death, such as spinal injury, severe diaphragmatic palsy, and other unexpected systematic artery embolization. Minor complications are mild self-limiting symptoms that could be relieved by symptomatic treatment or rest. The original data were verified twice.

2.4. Statistical analysis

The technical and immediate control rates, total recurrence rates, major complication rates, minor complication rates, and mortality rates extracted from each original article were pooled to estimate and assess the efficacy and safety of BAE. Pooled statistics are expressed as proportions at 95% confidence intervals (CIs). I² was used to evaluate the heterogeneity of the included articles. The heterogeneity of included articles was classified into three levels: low (I²<50%), moderate (50% < I²<75%), and considerable heterogeneity (I²>75%). A random-effect model was used to pool the proportions with I²>50%, whereas a fixed-effect model was applied to articles with low heterogeneity. Publication bias was evaluated by a funnel plot and quantified using the method of Begg’s test. Statistical significance was defined at p < 0.05. We used STATA/SE 15.1(StataCorp LLC, Texas, USA) to perform the statistical analysis in this study.

3. Results

3.1. Study identification and selection

A total of 843 articles (PubMed, 174; Embase, 546; Web of Science, 115; and Cochrane Library, 8) were searched according to the PRISMA guidelines (Fig. 1). After excluding duplicate articles, 611 articles were included. We subsequently screened the abstracts of each article and found that 304 articles were reviews, systematic reviews, meta-analyses, comments, animal studies, conference papers, and case reports. A total of 176 articles mismatched the literature inclusion standards for research topics and interventions, and were thus excluded, along with 62 studies with unavailable full-texts. After excluding a total of 542 papers, we read the full text of 69 articles, of which 48 articles were excluded. Finally, 21 full-text articles were included in the study.

3.2. Baseline characteristics of included studies

Twenty-one studies that included a total of 2511 patients who underwent BAE were included. Table 1 provides basic summaries of these studies. Published between 2008 and 2019, these studies reported that various patients received BAE treatment due to the diverse etiologies of tuberculosis (TB), tumor, etc. Demographic data, namely, age, sex, and number, are also listed. Nineteen articles that included a total of 2511 patients were used to pool the data of the technical success rate, while 16 studies were used for the evaluation of immediate control of hemoptysis information. We also evaluated 16 studies to estimate recurrence and mortality after a BAE procedure. Finally, we analyzed major and minor complications secondary to BAE to evaluate its safety.

3.3. Technical success rate

Twenty-one of the included studies reported technical success rates ranging from 76.9% to 99.9%. The pooled proportion of technical success rate was 99.9% (95% CI: 99.6–100%; Cis and Table 2). The heterogeneity analysis showed low heterogeneity in 21 original studies; hence, a fixed-effect model was used (I² = 44.2%, p = 0.02, Cis and Table 2).
3.4. Immediate control rate

In 16 studies, 1099 patients were referred, and 1061 patients with hemoptysis achieved immediate control of bleeding (Table 2). As shown in Fig. 3, the pooled estimated proportion of immediate control for hemoptysis was 99.5% (95% CI: 97.8–99.2%). Each original study reported
Table 2
Summary of variables.

| Variables            | Study(n) | Event | Total  | Proportion | 95%CI   | $i^2$ | p   | Model | Publication bias (Begg's test) |
|----------------------|----------|-------|--------|------------|---------|-------|-----|-------|-------------------------------|
| Technical success    | 19       | 1294  | 1323   | 0.999      | 0.99-1.00 | 44%   | 0.020 | Fixed | $< 0.01$                      |
| Immediate control    | 16       | 1061  | 1099   | 0.995      | 0.978-0.992 | 41.3% | 0.020 | Fixed | $< 0.01$                      |
| Hemoptysis recurrence| 16       | 338   | 1458   | 0.237      | 0.185-0.289 | 73.6% | $< 0.01$ | Random | 0.137                      |
| Mortality of recurrence | 21     | 33    | 2511   | 0.002      | 0.000-0.003 | 39%   | 0.035 | Fixed | $< 0.01$                      |
| Total complication   | 9        | 59    | 396    | 0.134      | 0.076-0.192 | 69.1% | 0.001 | Random | 0.076                      |
| Minor complication   | 8        | 40    | 412    | 0.100      | 0.047-0.096 | 54.3% | 0.032 | Random | 0.004                      |

Fig. 2. Forest plot for technical success after BAE.

Fig. 3. Forest plot for hemoptysis immediate control after BAE.
that the immediate control rate ranged from 86.0% to approximately 99.5%. The fixed-effect model was utilized due to the relatively low heterogeneity ($I^2 = 41.3\%$, $p = 0.043$).

### 3.5. Recurrence of hemoptysis

Sixteen studies with a total of 1458 patients reported 338 cases of recurrence of hemoptysis after BAE (Table 2). According to the forest plot (Fig. 4), the pooled second recurrence rate of hemoptysis was 23.7% (95% CI: 18.55–28.9%), ranging from 7.4% to 56.7%. A random-effect model was applied due to moderate heterogeneity ($I^2 = 73.6\%$, $p < 0.01$).

### 3.6. Mortality of hemoptysis after BAE

The mortality associated with hemoptysis recurrence is shown in Fig. 5 and Table 2. Twenty-one studies and 2511 patients were summed up and analyzed, and the pooled rate of mortality of recurrence was 0.2% (95% CI: 0.0–0.3%) with low heterogeneity ($I^2 = 39.0\%$, $p = 0.035$).

### 3.7. Complications

Fifty-nine of 396 cases with complications were reported in nine studies (Table 2). Studies showed that 0.02% (95% CI: 7.6–19.2%, Fig. 6) of the patients who received bronchial or non-bronchial artery embolotherapy had complications. The random-effect model was utilized due to moderate heterogeneity ($I^2 = 69.1\%$, $p = 0.001$).

The major and minor complications are listed in Table 2.

Major complications occurred after BAE in 59 patients in 21 studies (0.2%, 95% CI: 0.2–0.4%, Fig. 7). After the heterogeneity test was performed, the $I^2$ was zero ($p = 0.934$); hence, a fixed-effect model was used. Forty of 412 patients had minor complications in eight studies (Fig. 8). The pooled rate of minor complications was 10% (95% CI: 4.7–9.6%), and the random-effect models were used due to moderate heterogeneity ($I^2 = 54.3\%$, $p = 0.032$).

### 3.8. Publication bias

The Begger’s test and funnel plot were used to evaluate for publication bias. Results showed that publication bias was detected in technical success ($p < 0.01$, Table 2 and Fig. 7A), immediate control ($p < 0.01$, Table 2 and Fig. 7B), recurrence mortality ($p < 0.01$, Table 2 and Fig. 7D), and minor complications ($p = 0.004$, Table 2 and Fig. 7G). The nonparametric trim-and-fill method was used to identify and correct for funnel plot asymmetry secondary to publication bias. After using this method, the pooled value of technical success (99.9%, 95% CI: 99.6–100%) and immediate control (99.5%, 95% CI: 97.2–99.2%) did not change, which showed robust statistical power. The recurrence mortality rate was 2% (95% CI: 0–3%) in the fixed-effects model, with four studies added in the future. The minor complication rate was 7.1% (95% CI: 11.9–12.3%) in the random effects model, with three studies which need to be added in the future. All funnel plots are shown in Fig. 9.

### 4. Discussion

BAE is a significant intervention which plays a vital role in hemoptysis-associated diseases. Additionally, its application allows more time to treat the underlying disease of massive hemoptysis. Our study focuses on the efficacy and safety of BAE to evaluate its availability and aid clinicians in practice through a review of articles on the management of abrupt hemoptysis. The technical and immediate control rates were 99.9% (95% CI: 99–100%) and 99.5% (95% CI: 97.2–99.2%) in our study, respectively. We also found recurrence in 23.7% (95% CI: 18.9–28.9%) of post-BAE hemoptysis patients, of whom 0.2% died. The assessment of complications revealed a total complication rate of 13.4% (95% CI: 7.6–19.2%), in which 0.2% (95% CI: 0.2–0.4%) were major complications and 10% (95% CI: 4.7–9.6%) were minor complications.

Most patients with hemoptysis achieved BAE technical success and immediate control of bleeding. Immediate bleeding control was observed in 95% of cases, and hemoptysis was controlled within a month using BAE in 90% of patients. Failed hemostasis for BAE is usually due to non-
Bronchial arterial bleeding, although it generally presents in only a small group of patients with hemoptysis. Hemoptysis gradually becomes common because of more and more cases of tuberculosis and bronchiectasis. In addition, it should be emphasized that advanced embolization materials significantly improve the safety and efficacy of the procedure and control the rate of hemoptysis. Generally, four embolization materials are available for embolization of hemoptysis-associated arteries. The most conventional embolization material is gelatin sponge, which is widely used by interventionists globally when hemoptysis occurs. This may be attributed to its low cost and ease of use during emergencies. However, due to its absorbability in human tissues, it is relatively temporary, which increases the risk of recurrent bleeding. To overcome this limitation, some mid- or long-term embolization materials, such as polyvinyl alcohol (PVA) and N-Butyl-2-Cyanoacrylate Glue (NBCA), are gradually being used as alternatives. They significantly improve the technical success and immediate control of hemoptysis due to their high availability and convenience. The use of coils in BAE also improved the immediate bleeding control rate, in combination with superselective embolization. Coils are a permanent embolization agent with a low recanalization rate and a high thrombogenicity. Once released to targeted vessels, coils instantly form thrombi when in contact with blood, achieving good hemostasis. However, for inexperienced interventionists, problems arise with the use of coils. Firstly, the targeted bleeding artery becomes tiny and distorted due to the underlying disease erosion and

---

**Fig. 5.** Forest plot for mortality of hemoptysis recurrence.

**Fig. 6.** Forest plot for total complication after BAE.
drastic reduction in local blood volume, making superselective embolization difficult to achieve. Secondly, traditional coils are still widely used in hemoptysis therapy, and these coils are often difficult to recycle if released once. Thirdly, there have been several discussions on the occlusion of the proximal artery following the use of coils, which would, in turn, complicate the embolization of the distal part of the same artery in case of rebleeding. Moreover, interlocking detached coils is now a viable option, in which doctors can adjust and reposition the guiding catheter with detached coils to find a suitable location for immediate bleeding control. A Japanese study reported that short coils entwined with long coils made it easy to control bleeding, with a 92.6% likelihood of immediate success. Current detachable coils are relatively used less in the treatment of hemoptysis due to their cost-effectiveness for superselective embolization.

We compared and summarized recurrence data from the literature on BAE. The pooled total recurrence rate was 23.7%, and the pooled mortality rate from hemoptysis recurrence was 2%. However, it should be emphasized that several studies have shown highly variable recurrence rates. Lee et al. reported that only one of 26 patients (4%) experienced a recurrence of hemoptysis after BAE. However, another Korean study on TB-associated hemoptysis reported a different result, showing that 52% (88/169) of TB patients experienced recurrent hemoptysis after BAE. There are three main reasons for the variable recurrence rates in available literature. First, different vascular embolization degrees account for...
the uneven recurrence proportions. Usually, incomplete embolization results in early recurrence in patients with hemoptysis. In emergencies, operators often have very limited time to locate and embolize the target artery. Large arteries are not hard to detect and embolized easily, whereas some small bleeding arteries cannot be detected initially, which may lead to massive hemoptysis or recurrence. Moreover, BAE is usually performed in tertiary referral centers, and patients suffering from hemoptysis have already been injected with positive vasoactive agents to control bleeding prior to transfer to a higher-level hospital. Interventionists may also miss some culprit vessels. These vessels cause suspended bleeding due to vasoconstriction from the administration of vasoconstrictors. In addition, the variation in recurrence rates from the literature may be attributed to divergent underlying diseases, irregular treatment, late treatment, and progression of respiratory diseases. TB, invasive pulmonary aspergillosis, bronchiectasis, and lung tumor are the top four etiologies of hemoptysis.\textsuperscript{18,22,35} To reduce hemoptysis recurrence, the treatment should be based on its specific etiology and not on the subjective clinical experience of the doctor. Most cases of hemoptysis recurrence were due to the progression of the primary disease when the lesion erodes into the artery. Neglecting the treatment of underlying diseases (such as anti-infection or anti-tumor agents) contribute to the recurrence of hemoptysis. Therefore, the appropriate treatment for hemoptysis and the primary disease improves the safety and efficacy of BAE. Considering the different etiologies of hemoptysis, early and timely therapy of mild hemoptysis through BAE could prevent the erosion of pulmonary tissues and progression to massive hemoptysis. Achieving sustained hemoptysis and primary disease control will decrease hemoptysis recurrence and improve the quality of life of the patient.

In our study, the low hemoptysis recurrence mortality in this patient population is consistent with published data.\textsuperscript{35,36} Some studies have reported that hemoptysis recurrence results from incomplete embolization and undetected bleeding in non-bronchial arteries, which occurs 1–6 months later. Contrarily, the progression of the underlying disease may account for the rebleeding when hemoptysis occurs 6–12 months after BAE.\textsuperscript{37} In particular, the mortality after BAE was associated with the progression of primary diseases (e.g., TB, tumor, and COPD), rather than BAE-associated adverse events.

Most bleeding arteries originate from the bronchial or intercostal arteries with high blood pressure; thus, the recurrent bleeding in these blood vessels after BAE are often severe compared with the less frequent pulmonary artery hemorrhage with relatively low blood pressure.

To achieve high success and low recurrence, a systematic and thorough search for culprit vessels and complete embolization should be performed. This is an effective method for interventions. The majority of recurrent hemoptysis patients would receive second-line intervention therapy using BAE in case of spontaneous recurrence or if they were not candidates for surgery. In the study, only 2% of patients underwent surgical treatment. The patients also had a high acceptance of the procedures, which can also demonstrate their safety and repeatability.

The pooled total complication rate for BAE was 13.4%, in which 10% were minor complications and 2% were major complications. Compared with surgical treatment for hemoptysis, BAE has a lower complication.

![Fig. 9. (a) Funnel plot for technical success; (b) Funnel plot for immediate control; (c) Funnel plot recurrence of hemoptysis; (d) Funnel plot recurrence mortality; (e) Funnel plot total complication; (f) Funnel plot major complication; (g) Funnel plot minor complication.](image-url)
rate and fewer adverse events. The most severe complication of BAE is spinal artery embolization, but it is rarely reported in relevant studies. It should be noted that paralysis-related adverse events occurred during erroneous embolization of the spinal artery by clinicians. This major complication is attributed to unclear spinal artery imaging on a fluorescent screen and reflux of a liquid embolization agent. Meanwhile, minor complications are common, and the symptoms are mild. Most minor complications are self-limiting, such as fever, chest pain, cough, dysphagia, back pain, and lower limb muscle weakness, which typically resolve within a week. Back pain was the most common symptom due to peripheral nerve stimulation from the embolization agent and a transient vascular embolization. Fevers, mostly absorption fevers, are also common after BAE due to hypersensitivity to the contrast agent. Other minor complications, such as dysphagia and lower limb muscle weakness, are rare and transient. Superselective and meticulous BAE are required to achieve high therapeutic efficacy during the perioperative period. Additionally, alleviating discomfort from minor complications and assisting the patient's recovery to their previous quality of life are of utmost importance.

This study has several limitations. First, a major limitation is the effect of bias on this meta-analysis due to the non-randomized controlled study designs and retrospective nature of most of the included studies. Second, the small population sizes of the included studies may have influenced the accuracy of the pooled values. Third, the heterogeneity of some pooled values (e.g., hemoptysis recurrence and complications) remained high, which indicates that large randomized control trials should be performed in the future. Fourth, the consensus standard has not been unified for BAE, and the included studies have different definitions of key terms such as recurrence and complications, to which the heterogeneity of this meta-analysis can be attributed. Fifth, this study may have overestimated or underestimated the efficacy and safety of BAE; thus, further studies involving different races and populations are needed.

5. Conclusion

This study demonstrated that BAE is a safe, effective, and feasible intervention for hemoptysis through the analysis of its technical success rate, immediate hemoptysis control, mortality, recurrence, and complications. It is also an efficacious means to control moderate or massive hemoptysis resulting from diverse etiologies for TB, bronchiectasis, tumor, and vascular malformation. It is particularly beneficial for some severe hemoptysis patients in the acute phase, even in shock, who are not candidates for bronchoscopy and surgery for the management of the underlying cause of hemoptysis, such as a pulmonary mass. Thus, BAE may be a crucial bridging intervention for massive hemoptysis patients and allow more time for other treatment options during emergencies.

Declaration of interests

We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

References

1. Davidson K, Shojaee S. Managing massive hemoptysis. Chest. 2020;157:77–88.
2. Jones R, Charlton J, Latinovic R, et al. Alarm symptoms and identification of non-cancer diagnoses in primary care: cohort study. BMJ. 2009;339:b3094.
3. Ittrich H, Buckhorn M, Klose H, et al. The diagnosis and treatment of hemoptysis. Dtsch Arztebl Int. 2017;114:371–381.
4. Corey R, Hia KM. Major and massive hemoptysis: reassessment of conservative management. Am J Med Sci. 1987;294:301–309.
5. Parrot A, Tavolaro S, Voiriot G, et al. Management of severe hemoptysis. Expert Rev Respir Med. 2018;12:817–829.
6. Valipour A, Kreutzer A, Koller H, et al. Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis. Chest. 2005;127:213–2118.
7. Garzon AA, Gourin A. Surgical management of massive hemoptysis. A ten-year experience. Ann Surg. 1978;187:267–271.
8. Gourin A, Garzon AA. Operative treatment of massive hemoptysis. Ann Thorac Surg. 1974;18:52–60.
9. Remy J, Arnaud A, Fardou H, et al. Treatment of hemoptysis by embolization of bronchial arteries. Radiology. 1977;122:33–37.
10. Pandu A, Bhalla AS, Goyal D. Goyal A. Bronchial artery embolization in hemoptysis: a systematic review. Diagn Interv Radiol. 2017;23:307–317.
11. Chun JY, Morgan R, Belli AM. Radiological management of hemoptysis: a comprehensive review of diagnostic imaging and bronchial arterial embolization. Cardiovasc Intervent Radiol. 2010;33:240–250.
12. Anuradha C, Shyamkumar NK, Vinu M, et al. Outcomes of bronchial artery embolization for life-threatening hemoptysis due to tuberculosis and post- tuberculosis sequelae. Diagn Interv Radiol. 2012;18:96–101.
13. Ayy I, Muller-Wille R, Wohlgennuth WA, et al. Treatment of acute hemoptysis by bronchial artery embolization with the liquid embolic agent ethylene vinyl alcohol copolymer. J Vasc Interv Radiol. 2017;28:825–831.
14. Dali A, Probst NH, Jobst B, et al. Bronchial artery embolization in patients with hemoptysis including follow-up. Acta Radiol. 2011;52:143–147.
15. Lee SH, Lee JH, Chang JH, et al. Bronchial artery embolization in patients with nonmucobucillary bacterial lung disease. BMC Pulm Med. 2019; 19:117.
16. Angle JF, Siddiqi NH, Wallace MJ, et al. Quality improvement guidelines for percutaneous transcatheter embolization: society of interventional radiology standards of practice committee. J Vasc Interv Radiol. 2010;21:1479–1486.
17. Miyano Y, Kanzaki M, Obara T, et al. Fabricated bronchial artery embolization for hemoptysis by using a coil. Asian Cardiovasc Thorac Ann. 2016;24:445–449.
18. Pathak V, Stavas JM, Ford HJ, et al. Long-term outcomes of the bronchial artery embolization are diagnosis dependent. Lung India. 2016;33:3–6.
19. Mehta AS, Ahmed O, Ilanli D, et al. Bronchial arterial embolization for malignant hemoptysis: a single institutional experience. J Thorac Dis. 2015;7:1406–1413.
20. Yoo DH, Yoon CJ, Kang SG, et al. Bronchial and nonbronchial systemic artery embolization in patients with major hemoptysis: safety and efficacy of N-butyl cyanoacrylate. AJR Am J Roentgenol. 2011;196;W199–2024.
21. Lee MK, Kim SH, Yong SJ, et al. Moderate hemoptysis: recurrent hemoptysis and mortality according to bronchial artery embolization. Clin Res J. 2015;9:653–666.
22. Shin BS, Jeon GS, Lee SA, et al. Bronchial artery embolization for the management of haemoptysis in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2011;15:1095–1098.
23. Springer DM, Costa S, Juszkut R, et al. The effectiveness of bronchial artery embolization in patients with haemoptysis. Adv Respir Med. 2018;86:220–226.
24. Shimohira M, Ohta K, Nagai K, et al. Bronchial arterial embolization using a gelatin sponge for hemoptysis from pulmonary aspergilloma: comparison with other pulmonary diseases. Emerg Med J. 2019;26:501–506.
25. Shao H, Wu J, Wu Q, et al. Bronchial artery embolization for hemoptysis: a retrospective observational study of 344 patients. Chin Med J (Engl). 2015;128: 58–62.
26. Shimohira M, Hashimoto T, Abematsu S, et al. Triaxial system in bronchial arterial embolization for haemoptysis using N-butyl-2-cyanoacrylate. Br J Radiol. 2015;88:2038–384.
27. Balthacioglu F, Cimijt NC, Bostani K, et al. Transtrocalarterial microcatheter glue embolization of the bronchial artery for life-threatening hemoptysis: technical and clinical results. Eur J Radiol. 2011;70:280–384.
28. Agmy GM, Wafy SM, Mohamed SAA, et al. Bronchial and nonbronchial systemic arterial embolization in management of hemoptysis experience with 348 patients. ISVRN Vascular Medicine. 2013;2013:1–7.
29. Lee H, Yoon CJ, Seong NJ, et al. Cryogenic hemoptysis: effectiveness of bronchial artery embolization using N-butyl cyanoacrylate. J Vasc Intervent Radiol. 2017;28:1161–1166.
30. Bommarat S, Bourdin A, Giroux MF, et al. Transtrocalarterial ethylene vinyl alcohol copolymer visualization and penetration after embolization of life-threatening hemoptysis: technical and clinical outcomes. Cardiovasc Intervent Radiol. 2012;35: 668–675.
31. Kucukay F, Topcuoglu OM, Alpert A, et al. Bronchial artery embolization with large sized (700–900 μm) Tris-acryl Microspheres (Embosphere) for massive hemoptysis: long-term results (clinical research). Cardiovasc Intervent Radiol. 2018;41:225–230.
32. Dave BR, Sharma A, Kalsa SP, et al. Nine-year single-center experience with bronchial and nonbronchial systemic arterial embolization for hemoptysis including follow-up. Diagn Interv Radiol. 2015;52:143–147.
33. Chun JY, Bello AM. Immediate and long-term outcomes of bronchial and nonbronchial systemic arterial embolization for the management of hemoptysis. Eur Radiol. 2010;20:558–565.
34. Dali A, Probst NH, Jobst B, et al. Bronchial artery embolization in patients with hemoptysis including follow-up. Acta Radiol. 2011;52:143–147.
35. Ishikawa H, Hara M, Ryuge M, et al. Efficacy and safety of super selective bronchial artery coil embolisation for hemoptysis: a single-centre retrospective observational study. BMJ Open. 2017;7, e014805.
36. Syh R, Benz T, Hetzel J, et al. Bronchial artery embolization in hemoptysis: 10-year survival and recurrence-free survival in benign and malignant etiologies - a retrospective study. Rofo. 2016;188:1061–1066.
37. Davis PB, Di Sant'Agnese PA. Diagnosis and treatment of cystic fibrosis. An update. Chest. 1984;85:802–809.
38. Haponik EF, Fein A, Chin R. Managing life-threatening hemoptysis: has anything really changed? Chest. 2006;116:1431–1435.